Natural history of HIV-control since seroconversion
- 24 September 2013
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 27 (15) , 2451-2460
Abstract
Objectives: HIV-controllers spontaneously maintain HIV viremia at an undetectable level. We aimed to describe the delay to control from seroconversion, the duration of control, and risk factors for losing control. Methods: HIV-controllers were identified from a pooled dataset of 24 seroconverter cohorts from Europe, Australia, and Canada (CASCADE). HIV-controllers had at least five consecutive viral loads less than 400/500 copies/ml, while antiretroviral therapy naive, for at least 5 years after seroconversion. End of control was defined as two consecutive viral loads above 2000 copies/ml. Duration of control was described using Kaplan–Meier estimates; factors associated with duration of control were identified using a Cox model. CD4+ cell count evolution during control was described using a mixed model. Results: Of 9896 eligible seroconverters, we identified 140 (1.4%) HIV-controllers, the largest database of HIV-controllers followed from seroconversion. For 64 with viral load measured within 24 months from seroconversion, median delay to control was 16.7 (interquartile range: 7.8–37.9) months. Probability of maintaining control 20 years after seroconversion was 0.74 [95% confidence interval (CI): 0.64–0.85]. Occurrence of blips followed by return to undetectability did not increase the risk of loss of control [hazard ratio: 0.81 (95% CI: 0.10–6.70)]. However, CD4+ cell loss during control was significantly accelerated in individuals with blips. Conclusion: In most individuals, control occurred rapidly after seroconversion; however, more than 3 years were required to achieve control in 25% of HIV-controllers. Control may be sustained even when CD4+ cell levels are below 500 cells/μl, opening important new perspectives to understand the physiopathology underlying control.Keywords
This publication has 24 references indexed in Scilit:
- Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllersBlood, 2011
- CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French ObservatoryPLOS ONE, 2011
- CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21Journal of Clinical Investigation, 2011
- Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV ControllersJournal of Virology, 2010
- Clinical Outcomes of Elite Controllers, Viremic Controllers, and Long‐Term Nonprogressors in the US Department of Defense HIV Natural History StudyThe Journal of Infectious Diseases, 2009
- Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIVAIDS, 2009
- Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllersAIDS, 2009
- Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in FranceAIDS, 2008
- HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotypeProceedings of the National Academy of Sciences, 2007
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006